ライフサイエンスコーパス: long-term outcome

1 etabolic health, cardiovascular disease, and long-term outcome.

2 Conclusion: PRRT is encouraging in terms of long-term outcome.

3 develop more robust correlates that predict long-term outcome.

4 ces are important factors that determine the long-term outcome.

5 ffairs uniquely allows investigation of this long-term outcome.

6 preventing early recurrences, and improving long-term outcome.

7 the optic nerve head at presentation predict long-term outcome.

8 e and remain associated with poor short- and long-term outcomes.

9 after injury have been associated with worse long-term outcomes.

10 nagement, without proven positive effects on long-term outcomes.

11 dapted maintenance can deliver unprecedented long-term outcomes.

12 ated venous invasion might predict favorable long-term outcomes.

13 on (PH) have accelerated lung aging and poor long-term outcomes.

14 reatment after hospital discharge to improve long-term outcomes.

15 ting for pre-ICU health status when studying long-term outcomes.

16 trategy is associated with better short- and long-term outcomes.

17 exposure post-liver transplantation (LT) and long-term outcomes.

18 ed on a tumor classification to evaluate the long-term outcomes.

19 for COA intervention and potentially improve long-term outcomes.

20 Their use is associated with poor long-term outcomes.

21 noma had similar excellent intermediate- and long-term outcomes.

22 ss detected by EEG is associated with better long-term outcomes.

23 ause they are expected to be associated with long-term outcomes.

24 opoietic cell transplant to achieve the best long-term outcomes.

25 owed for 24 months to compare short-term and long-term outcomes.

26 d risk estimates and can potentially improve long-term outcomes.

27 improve cost effectiveness, even with modest long-term outcomes.

28 trol might reduce disease burden and improve long-term outcomes.

29 Here, we report data on long-term outcomes.

30 nd to better predict treatment responses and long-term outcomes.

31 scertain whether these interventions improve long-term outcomes.

32 and trastuzumab is associated with excellent long-term outcomes.

33 nt of symptomatic carotid stenosis to assess long-term outcomes.

34 o clinically meaningful predictive value for long-term outcomes.

35 eased donor kidneys, affects both short- and long-term outcomes.

36 to avoid clinical decompensation and improve long-term outcomes.

37 vide complementary prognostic information on long-term outcomes.

38 lar obstruction present at baseline on these long-term outcomes.

39 ucing significant patient mortality and poor long-term outcomes.

40 od, despite the relevance of such effects to long-term outcomes.

41 emia and ID in HF would improve symptoms and long-term outcomes.

42 eeded to replicate these findings and assess long-term outcomes.

43 rapy, but this does not explain their better long-term outcomes.

44 important in optimizing quality of life and long-term outcomes.

45 ne colonoscopy findings were associated with long-term outcomes.

46 r attack prevention has greatly improved the long-term outcomes.

47 PK donor pool without compromising short- or long-term outcomes.

48 ngest follow-up and important information on long-term outcomes.

49 r door-to-needle times translate into better long-term outcomes.

50 organ transplant recipients and compromises long-term outcomes.

51 Regarding long-term outcomes, Ackr2(-/-) kidneys displayed more tu

52 BPVT), anticoagulation is effective, but the long-term outcome after BPVT is unknown.

53 The HP2 allele associated with a favourable long-term outcome after high-volume but not low-volume a

54 ographic (CT) biomarkers are associated with long-term outcome after intracerebral hemorrhage.

55 or take preventative measures, that improve long-term outcome after kidney transplantation.

56 s or take preventative measures that improve long-term outcome after kidney transplantation.

57 aim of the present study was to analyze very long-term outcome after MV repair and replacement for de

58 be the desirable end point for a successful long-term outcome after VT ablation.

59 margin status, but further data is needed on long-term outcomes after ablative treatment in HIV-infec

60 Long-term outcomes after anatomical hepatectomy with the

61 y useful prognostic estimation of functional long-term outcomes after ICH.

62 OFILE registry will improve our knowledge of long-term outcomes after implant placement.

63 graft loss, and a major barrier to improving long-term outcomes after intestinal transplantation.

64 death (DCD) procurement, impacts short- and long-term outcomes after liver transplantation (LT).

65 tion (EF) recovery is associated with better long-term outcomes after myocardial infarction (MI).

66 New approaches are required to improve long-term outcomes after PCI.

67 Long-term outcomes after percutaneous coronary intervent

68 Studies of long-term outcomes after pneumonectomy typically report

69 ritical illness will be necessary to improve long-term outcomes after sepsis.

70 nce between low inpatient mortality and poor long-term outcomes after surgical sepsis, especially amo

71 that children may be more vulnerable to poor long-term outcomes after traumatic brain injury (TBI) co

72 ute adverse events and their relationship to long-term outcomes after traumatic spinal cord injury.

73 are common and are associated with worsened long-term outcomes after traumatic spinal cord injury.

74 ur results provide a better understanding of long-term outcomes after vehicle-traumatic AKI-RRT.

75 here were no significant gains in unadjusted long-term outcomes among 1-year survivors over the past

76 The long-term outcomes among acute HF survivors remain poor

77 Markov model simulated long-term outcomes among HCV-negative patients on the tr

78 association between operator PCI volume and long-term outcomes among patients >=65 years of age.

79 ion and its association with in-hospital and long-term outcomes among patients with decompensated HFp

80 Few studies have compared long-term outcomes among specific treatment modalities f

81 In this unique long-term outcome analysis, BP-SES and PP-EES showed com

82 ytoplasmic cyclin E expression also predicts long-term outcome and is associated with reduced disease

83 We assess long-term outcome and prognosis factors for vascular com

84 Data on the long-term outcome and satisfaction of patients undergoin

85 m of this study was to assess the short- and long-term outcome and to determine the prognostic factor

86 More data will be available to evaluate long-term outcomes and disease impact on graft function.

87 However, the association between long-term outcomes and EF recovery among young MI patien

88 We aimed to define long-term outcomes and explore risk stratification in pa

89 (CoB)-based regimen could achieve acceptable long-term outcomes and graft survival could be maintaine

90 cally considered to have superior short- and long-term outcomes and lower requirement for immunosuppr

91 ure was also associated with poor short- and long-term outcomes and may be more significant than intr

92 More information about long-term outcomes and patient and societal preferences

93 ritical care survivors is growing, but their long-term outcomes and resource use are poorly character

94 ed to replicate these findings and to assess long-term outcomes and safety.

95 LVMR offers acceptable long-term outcomes and satisfaction.

96 However, open questions remain regarding long-term outcomes and the risk of propagating drug resi

97 However, questions remain regarding long-term outcomes and the risk of propagating drug resi

98 ates a need to identify factors that predict long-term outcomes and to discuss realistic expectations

99 c and histological healing to achieve better long-term outcomes and, consequently, diagnostic modalit

100 d questionnaire to record pre-LVMR symptoms, long-term outcome, and overall satisfaction.

101 therapy including the use of bromocriptine, long-term outcomes, and duration of treatment after reco

102 post-operative care, anticipated short- and long-term outcomes, and future directions for clinical c

103 s were associated with worse both short- and long-term outcomes, and should be prevented by careful p

104 Until data on long-term outcomes are available, early salvage treatmen

105 Long-term outcomes are generally good; however, the risk

106 incidence and trends remain unknown, and the long-term outcomes are incompletely characterized.

107 on, stopping medication (deprescribing), and long-term outcomes are more likely to be addressed.

108 Long-term outcomes are not yet known.

109 piratory syndrome coronavirus-2 appear good, long-term outcomes are unknown.

110 ergo delayed graft function but have similar long-term outcomes as donors without AKI.

111 Though limited by incomplete long-term outcomes ascertainment, active surveillance of

112 beyond low annualized bleed rates to include long-term outcomes associated with high sustained FVIII

113 Improving long-term outcomes at IVH may provide opportunities for

114 We compared differences in long-term outcomes between subjects who developed chroni

115 hypothesised that the HP CNV associates with long-term outcome beyond the first year after aSAH.

116 The results suggest that good long-term outcomes can be achieved using aflibercept for

117 This depends on long-term outcomes compared with chemoimmunotherapy and

118 Here we analyzed the long-term outcome data (144 weeks).

119 well established for up to 1 or 2 years, but long-term outcome data are still limited.

120 Long-term outcome data were collected for 28 patients (2

121 l relevance of recent, sometimes concerning, long-term outcome data.

122 were extended with additional treatment and long-term outcome data.

123 inhibitor-based single-tablet regimens, but long-term outcomes data are not available.

124 rtially because of heterogeneous and limited long-term outcomes data assessing recent cryoablation me

125 Because the clinical long-term outcomes differ, we hypothesized different mol

126 The purpose of this study was to analyze the long-term outcome, efficacy, and safety of PRRT in patie

127 -loss, a substantial variability in achieved long-term outcomes exists among obese but otherwise heal

128 shed in 2012, we aimed to confirm results on long-term outcome focusing on efficacy and safety of lon

129 patency is one of the major determinants of long-term outcome following coronary artery bypass graft

130 ip between pre-procedural blood pressure and long-term outcome following percutaneous coronary interv

131 y training is associated with differences in long-term outcomes following ICD implantation is unclear

132 Data describing long-term outcomes following ICU for patients with alcoh

133 Given that long-term outcomes following lung transplantation remain

134 at the time of index PCI is associated with long-term outcomes following PCI.

135 However, scarce data exist on the long-term outcomes following PFO closure.

136 Long-term outcomes following tracheostomy are extremely

137 Future research on long-term outcomes following valve replacement is needed

138 cute stroke impairments often result in poor long-term outcome for stroke survivors.

139 Long-term outcomes for adults who underwent EA/TEF repai

140 This study demonstrates ER has comparable long-term outcomes for clinical T1aN0 and T1bN0 esophage

141 Long-term outcomes for patients with ECI were not inferi

142 therapy for prostate cancer offers excellent long-term outcomes for patients with high-risk disease.

143 artnership aimed at improving short-term and long-term outcomes for patients with PsD.

144 However, assessment of extended long-term outcomes for these devices is lacking, especia

145 een prospectively tested or shown to improve long-term outcomes-for example, quality of life, need fo

146 Herein, we present long-term outcomes from the trial.

147 Infected children with a better long-term outcome had higher numbers of B cells at birth

148 inically silent and remained undetected, but long-term outcomes have not been determined.

149 However, long-term outcomes have not been sufficiently assessed.

150 However, long-term outcomes have not been well documented.

151 ate transition model simulating individuals' long-term outcomes, healthcare costs, and quality of lif

152 PCI FFR value is independently predictive of long-term outcomes (higher is better).

153 For long-term outcome, higher FTR degree compared with trivi

154 nce standard was histology after surgery, or long-term outcome in a watch-and-wait policy.

155 ons of cTn levels with clinical findings and long-term outcome in acutely admitted patients with susp

156 cell transplantation (HCT), its efficacy and long-term outcome in matched (MUD) and mismatched unrela

157 s and quantifies PR and CR as surrogates for long-term outcome in MGN.

158 hese noncardiac complications may affect the long-term outcome in these patients and what modifiable

159 hort study determining the effectiveness and long-term outcome in this group of patients.

160 ly data suggest that AF ablation may improve long-term outcomes in AMC patients compared with medical

161 at 6-month outcomes may be useful to predict long-term outcomes in CAF procedures with or without add

162 The aim of this study was to determine the long-term outcomes in childhood IF and identify patient

163 ducing social disparities and improving poor long-term outcomes in disadvantaged families because fol

164 nal investigation into strategies to improve long-term outcomes in eyes with DME seems warranted to d

165 covariates, the PRT group exhibited superior long-term outcomes in global intelligence quotient (IQ),

166 We aimed to investigate the long-term outcomes in hepatitis B (HBV)/hepatitis C viru

167 retroviral therapy (HAART) has led to better long-term outcomes in HIV infected patients, it has not

168 gs in patients revealed novel phenotypes for long-term outcomes in ischemic cardiomyopathy.

169 PR-T-based immunosuppression might improve long-term outcomes in liver transplant recipients than I

170 standard of care, but there are few data on long-term outcomes in mutation carriers without HCM.

171 pment has important effects on immediate and long-term outcomes in offspring.

172 BP-SES versus thin-strut (81 mum) DP-EES on long-term outcomes in patients undergoing percutaneous c

173 es and stages of disease, new phenotypes and long-term outcomes in patients who would not have surviv

174 tpatient physician follow-up with short- and long-term outcomes in patients with atrial fibrillation

175 tensin system protective arm could influence long-term outcomes in patients with heart failure.

176 hat the ESA darbepoetin alfa did not improve long-term outcomes in patients with HF with reduced ejec

177 Biomarkers to estimate long-term outcomes in patients with multiple sclerosis (

178 ia mechanisms and to evaluate procedural and long-term outcomes in pediatric patients with CHD underg

179 my with the Glissonean pedicle approach, and long-term outcomes in relation to the morbidity in patie

180 trials are needed in current era to evaluate long-term outcomes in routine use of EPD, and meanwhile,

181 w method, there is a lack of knowledge about long-term outcomes in terms of effectiveness, technique

182 ments in adjuvant chemotherapy have improved long-term outcomes in these patients.

183 rgeted therapeutic approaches to improve the long-term outcomes in this population.

184 Long-term outcome included arrhythmia recurrence and bur

185 However, long-term outcome including quality of life and risk of

186 Either mechanism portends unfavorable long-term outcomes including risk for recurrent TB and f

187 We investigated early MRI predictors of key long-term outcomes including secondary progressive multi

188 echanisms by which mental illness influences long-term outcomes, including cancer and early mortality

189 Follow-up is ongoing for long-term outcomes, including efficacy and long-term saf

190 Many survivors experience poor long-term outcomes, including new or worsened neuropsych

191 Long-term outcomes, including overall survival (OS), rec

192 perated prosthetic valve endocarditis (PVE), long term outcome is largely unknown.

193 perated prosthetic valve endocarditis (PVE), long-term outcome is largely unknown.

194 her the choice of initial therapy influences long-term outcomes is uncertain.

195 atment modality shown to have any beneficial long-term outcome, is often not possible given the advan

196 dmission is the most important predictor for long-term outcomes, it is often not taken into account,

197 early postoperative over IS or high IPV and long-term outcome measures following LT.

198 nical value of this marker as a predictor of long-term outcome merit further evaluation.

199 , but without encephalitis, showed excellent long-term outcomes (modified Rankin Score=0) despite no

200 Studies directly comparing the long-term outcome of PPVI with the Melody valve to surgi

201 The purpose of this study was to analyze the long-term outcome of PRRT with regard to the most common

202 ction early after heart transplantation, but long-term outcome of such a strategy has not been well d

203 e the effect of asymptomatic carriers on the long-term outcome of the disease.

204 We now report the long-term outcome of the patients recruited in this tria

205 Expanded Programme on Immunization, but the long-term outcome of vaccination in this age group is un

206 We compared the long-term outcome of vehicle-traumatic and non-traumatic

207 The aim of this study was to determine the long-term outcomes of a large cohort of patients transpl

208 We evaluated long-term outcomes of a large cohort of patients with BD

209 The long-term outcomes of acellular dermal matrix (ADM) for

210 Therefore, we investigated the negative long-term outcomes of cancer-bereaved sons' and daughter

211 w, we critically discuss the evidence on the long-term outcomes of DBS and consider the clinical impl

212 he purpose of this study was to evaluate the long-term outcomes of Descemet membrane endothelial kera

213 inform ongoing debate and policy, we modeled long-term outcomes of early vs delayed liver transplanta

214 d donor pool; however, studies examining the long-term outcomes of en bloc transplantation in childre

215 of systemic steroids does not seem to worsen long-term outcomes of endophthalmitis compared to those

216 Purpose To report intermediate- to long-term outcomes of image-guided percutaneous cryoabla

217 cidence rates and case-mix adjusted rates of long-term outcomes of index ICD implantations across phy

218 the rise in these disease entities, detailed long-term outcomes of large NAFLD-associated HCC cohorts

219 Chronic renal disease (CKD) jeopardizes the long-term outcomes of liver transplant recipients.

220 In this study, we report long-term outcomes of LT for patients with HCC who were

221 The LTRS can stratify the short- and long-term outcomes of LT recipients at the time of their

222 To compare the safety and long-term outcomes of MAG vs LITA+SVG among overall and

223 of this study were to define the short- and long-term outcomes of medically refractory obstructive h

224 y syndromes or stable angina and to evaluate long-term outcomes of nonenrolled eligible patients trea

225 Few studies have evaluated long-term outcomes of ongoing colonoscopic screening and

226 Future studies should evaluate long-term outcomes of oral health as well as the social

227 Short- and long-term outcomes of patients undergoing cadaveric LT c

228 perioperative characteristics, and short and long-term outcomes of patients undergoing ReLT-KT at 2 t

229 erioperative characteristics, and short- and long-term outcomes of patients undergoing ReLT-KT at 2 t

230 of prospective studies assessing short- and long-term outcomes of patients when these markers are in

231 Long-term outcomes of patients with ARDS are increasingl

232 The goal of this study was to assess the long-term outcomes of patients with BPVT treated with an

233 This study compared early and long-term outcomes of PCI versus CABG in patients with d

234 5766 participants in a prospective study of long-term outcomes of pediatric patients with IBD (NCT00

235 To assess the long-term outcomes of phacoemulsification and intraocula

236 Investigating the long-term outcomes of sepsis survivors has revealed an u

237 g immune-related adverse events (irAEs), and long-term outcomes of severe, grade III to V irAE-N at a

238 Long-term outcomes of the 2 approaches are similar, maki

239 ors to optimize service delivery and improve long-term outcomes of the critically ill.

240 ollow-up study of therapies, focusing on the long-term outcomes of the rituximab plus bendamustine an

241 Review the long-term outcomes of the side-to-side isoperistaltic st

242 We report here long-term outcomes of the subgroup of patients with PCBS

243 his cycle while simultaneously improving the long-term outcomes of their offspring.

244 Understanding the long-term outcomes of these conditions may inform patien

245 This report focuses on long-term outcomes of these patients.

246 ng the cause or causes, optimal therapy, and long-term outcomes of these patients.

247 The long-term outcomes of this commonly performed bariatric

248 for dysfunctional hemodialysis fistulas, yet long-term outcomes of this treatment are poor.

249 In an analysis of long-term outcomes of trial participants, we found the s

250 the United States, but studies assessing the long-term outcomes of VHR using biologic mesh are scarce

251 future applications that attempt to predict long-term outcomes or develop tailored therapies.

252 We aimed to report the long-term outcomes over approximately 7 years of treatme

253 66 deaths from the original study to compare long-term outcomes overall and for key pre-specified sub

254 Combining hs-TnI and BNP improved to predict long-term outcome (p = 0.004).

255 though antiviral therapies have improved the long-term outcomes, patients often require life-long tre

256 Although long-term outcomes (periprocedural and postprocedural ri

257 okes or have short follow-up periods, so the long-term outcomes post-minor ischaemic stroke are uncle

258 We generated risk scores for short-term and long-term outcome prediction, validating their use in tw

259 However, long-term outcomes related to changes in transfusion pra

260 The main outcome was intermediate and long-term outcomes related to glaucoma.

261 fort should be made to prevent AMR to ensure long-term outcomes remain excellent.

262 ecific parameters that determine medium- and long-term outcomes remain ill defined.

263 However, data about long-term outcomes remain limited, especially among infa

264 Despite advances in immunosuppression, long-term outcomes remain suboptimal, hampered by drug t

265 recent progress in diagnosis and treatment, long-term outcome remains unsatisfactory.

266 Accurate prediction of long-term outcomes remains a challenge in the care of ca

267 rly AC after bioprosthetic AVR has impact on long-term outcomes remains to be determined.

268 sed or treated at our institution to analyze long-term outcome, response to treatment, and incidence

269 At the 4-year follow-up, we report long-term outcomes, response to subsequent therapies, an

270 The authors aimed to evaluate the acute and long-term outcomes resulting from both sequences of comb

271 hepatic SHH could benefit clinical trials or long term outcomes studies of NASH subjects.

272 However, more concrete and long-term outcome studies with these modalities are esse

273 t complication of traumatic injury; however, long-term outcomes such as mortality and end-stage kidne

274 creening examinations can be a surrogate for long-term outcomes, such as breast cancer morbidity and

275 include assessments of programme structure; long-term outcomes, such as survival, quality-adjusted l

276 kidney transplantation, impacting short- and long-term outcomes, these should be a priority.

277 ffolds have the potential to further improve long-term outcomes, they have not yet achieved results e

278 We projected long-term outcomes using an established model of HCV dis

279 Rate ratios (RRs) and 95% CIs estimated long-term outcomes using multivariable piecewise exponen

280 her simultaneous lung-liver transplant (LLT) long-term outcomes warrant allocation of 2 organs to a s

281 The long-term outcome was excellent, with survival of 87% at

282 This long-term outcome was not observed when male and female

283 circulating concentrations of PLP influences long-term outcome.We compared vitamin B-6 intake and cir

284 Long-term outcomes were analyzed.

285 edural characteristics, and acute as well as long-term outcomes were assessed.

286 Surgical event rates and long-term outcomes were based on data from a 10-year lon

287 Long-term outcomes were evaluated radiographically, endo

288 The mortality, morbidity, and long-term outcomes were evaluated retrospectively.

289 ality and improvements in a variety of other long-term outcomes were not consistent with the current

290 Short-term and long-term outcomes were not different in SOS and non-SOS

291 Age, sex, and education were associated with long-term outcomes, while almost none of the traditional

292 This meta-analysis aimed to compare the long-term outcomes with both devices.

293 n coronary artery disease (CAD) had improved long-term outcomes with coronary artery bypass graft (CA

294 ults of two European trials have shown worse long-term outcomes with endovascular repair than with op

295 The aim of this study was to compare long-term outcomes with percutaneous transluminal angiop

296 its use in complex AWR, ADM provides durable long-term outcomes with relatively low recurrence rates.

297 of rejection, we compared response rates and long-term outcomes with steroids alone versus steroids p

298 modifications that are needed to improve the long-term outcomes with these devices so that they event

299 ts (19%) and was associated with an improved long-term outcome, with an overall survival rate of 71%

300 t of large nerve fibre damage and to monitor long-term outcomes, with the sural or dorsal sural nerve